Galectin-3 inhibitors for the treatment of canine hemangiosarcoma (HAS): In silico strategy

2^nd Indo-Global Summit & Expo on Veterinary

October 26-28, 2015 Hyderabad, India

Preetha S P, Pavithra, Sujatha P L, Balachandran C, Sureshkannan S, Thangapandiyan M, Kumarasamy P and Selvasubramanian S

Madras Veterinary College, India

Posters-Accepted Abstracts: J Veterinar Sci Technol

Abstract :

Hemangiosarcoma (HSA) in dogs is deadly neoplastic disease characterized by an aggressive growth of malignant cells with endothelial phenotype, widespread metastasis and poor response to chemotherapy. Galectin-3 (Gal-3), a �²-galactoside-binding lectin implicated in tumor progression and metastasis, endothelial cell biology and angiogenesis and regulation of apoptosis and neoplastic cell response to cytotoxic drugs has not been studied before in tumors arising from malignant endothelia. Hence, an approach has been taken to design the Gal-3 inhibitors using modified citrus pectin (MCP). The study was undertaken by using commercial interaction tool called Discovery Studio. These results highlight the important role of Gal-3 in the biology of HSA and identify Gal-3 as a potential therapeutic target in tumors arising from malignant endothelial cells.

Biography :

Email: s.p.preetha@tanuvas.org.in